BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 61, Issue 4, 2014, Pages 647-652

  Moore, Andrew S ^a,b   Alonzo, Todd A ^c,d   Gerbing, Robert B ^c   Lange, Beverly J ^e   Heerema, Nyla A ^f   Franklin, Janet ^c   Raimondi, Susana C ^g   Hirsch, Betsy A ^h   Gamis, Alan S ⁱ   Meshinchi, Soheil ^j,k  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

ⁱ CHILDREN S MERCY HOSPITAL   (United States)

^j Fred Hutchinson Cancer Research Center   (United States)

^k UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Acute myeloid leukemia; Childhood AML; Molecular genetics; Refractory disease; Splice variant; Survivin

Indexed keywords

CD135 ANTIGEN; CYTARABINE; FLUDARABINE; IDARUBICIN; SURVIVIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW; CYTOGENETICS; FRAMESHIFT MUTATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MONOSOMY 7; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; YOUNG ADULT;

ACUTE MYELOID LEUKEMIA; CHILDHOOD AML; MOLECULAR GENETICS; REFRACTORY DISEASE; SPLICE VARIANT; SURVIVIN;

ALTERNATIVE SPLICING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84893434231     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24822     Document Type: Article

References (18)

1. Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol 2011; 29:551-565.
2. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29:487-494.
3. Gorman MF, Ji L, Ko RH, et al. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer 2010; 55:421-429.
4. Altieri DC. Survivin cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8:61-70.
5. Sampath J, Pelus LM. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol 2007; 4:174-191.
6. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 2000; 111:196-203.
7. Paydas S, Tanriverdi K, Yavuz S, et al. Survivin and aven: Two distinct antiapoptotic signals in acute leukemias. Ann Oncol 2003; 14:1045-1050.
8. Carter BZ, Qiu Y, Huang X, et al. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 2012; 120:173-180.
9. Wagner M, Schmelz K, Wuchter C, et al. In vivo expression of survivin and its splice variant survivin-2B: Impact on clinical outcome in acute myeloid leukemia. Int J Cancer 2006; 119:1291-1297.
10. Oto OA, Paydas S, Tanriverdi K, et al. Survivin and EPR-1 expression in acute leukemias: Prognostic significance and review of the literature. Leuk Res 2007; 31:1495-1501.
11. Invernizzi R, Travaglino E, Lunghi M, et al. Survivin expression in acute leukemias and myelodysplastic syndromes. Leuk Lymphoma 2004; 45:2229-2237.
12. Tamm I, Richter S, Oltersdorf D, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 2004; 10:3737-3744.
13. Ibrahim AM, Mansour IM, Wilson MM, et al. Study of survivin and X-linked inhibitor of apoptosis protein (XIAP) genes in acute myeloid leukemia (AML). Lab Hematol 2012; 18:1-10.
14. Zhou J, Bi C, Janakakumara JV, et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 2009; 113:4052-4062.
15. Fukuda S, Singh P, Moh A, et al. Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. Blood 2009; 114:394-403.
16. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the children's oncology group. Blood 2008; 111:1044-1053.
17. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group. Cancer 2012; 118:761-769.
18. Ho PA, Alonzo TA, Gerbing RB, et al. The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: Report from the Children's Oncology Group. Pediatr Blood Cancer 2013; doi: 10.1002/pbc.24700 [Epub ahead of print].